18F-Flortaucipir PET在MAPT突变携带者中的结合分布
该研究比较了9例(前)症状性MAPT突变携带者与30例认知正常对照及52例阿尔茨海默病患者的18F-flortaucipir PET结合潜能。结果显示症状性携带者结合最高,尤以R406W突变显著;前症状携带者已出现轻微tau结合升高,提示flortaucipir可能作为3R/4R tau病理相关MAPT突变的早期生物标志物。
要点
- 症状性MAPT突变携带者flortaucipir BPND总体最高,R406W突变最显著。
- 前症状MAPT突变携带者已可见轻微tau结合升高,提示早期沉积。
- flortaucipir或可作为3R/4R tau病理相关MAPT突变的早期生物标志物。
核心结论
- 前症状MAPT突变携带者已出现轻微tau结合升高,症状性携带者升高更明显,R406W突变最显著,flortaucipir可能作为3R/4R tau病理相关MAPT突变的早期生物标志物。
研究设计与样本
- 研究纳入9例(前)症状性MAPT突变携带者(含P301L、R406W、L315R、S320F、G272V突变),与30例认知正常对照和52例阿尔茨海默病患者比较。
- 采用130分钟动态18F-flortaucipir PET扫描,计算区域结合潜能BPND。
主要发现
- 症状性R406W携带者在前扣带回、岛叶、杏仁核、颞叶、顶叶和额叶的tau结合超过正常对照范围。
- 前症状R406W携带者内侧颞叶BPND升高。
- 1例症状性P301L携带者和3例前症状P301L携带者中的1例在岛叶、顶叶和额叶BPND较对照升高。
- 症状性G272V携带者皮层BPND广泛升高,神经病理检查显示3R病理和脑炎组合。
- 前症状L315R携带者额叶BPND高于对照,前症状S320F携带者BPND在对照范围内。
临床怎么用
- 18F-flortaucipir PET或可用于MAPT突变携带者的早期tau沉积评估,尤其针对可能导致3R/4R tau病理的突变。
局限性
- 样本量小,每种突变携带者例数有限,结果需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the [18F]flortaucipir binding distribution across MAPT mutations in presymptomatic and symptomatic carriers. METHODS: We compared regional [18F]flortaucipir binding potential (BPND) derived from a 130-minute dynamic [18F]flortaucipir PET scan in 9 (pre)symptomatic MAPT mutation carriers (4 with P301L [1 symptomatic], 2 with R406W [1 symptomatic], 1 presymptomatic L315R, 1 presymptomatic S320F, and 1 symptomatic G272V carrier) with 30 cognitively normal controls and 52 patients with Alzheimer disease. RESULTS: [18F]Flortaucipir BPND images showed overall highest binding in the symptomatic carriers. This was most pronounced in the symptomatic R406W carrier in whom tau binding exceeded the normal control range in the anterior cingulate cortex, insula, amygdala, temporal, parietal, and frontal lobe. Elevated medial temporal lobe BPND was observed in a presymptomatic R406W carrier. The single symptomatic carrier and 1 of the 3 presymptomatic P301L carriers showed elevated [18F]flortaucipir BPND in the insula, parietal, and frontal lobe compared to controls. The symptomatic G272V carrier exhibited a widespread elevated cortical BPND, with at neuropathologic examination a combination of 3R pathology and encephalitis. The L315R presymptomatic mutation carrier showed higher frontal BPND compared to controls. The BPND values of the S320F presymptomatic mutation carrier fell within the range of controls. CONCLUSION: Presymptomatic MAPT mutation carriers already showed subtle elevated tau binding, whereas symptomatic MAPT mutation carriers showed a more marked increase in [18F]flortaucipir BPND. Tau deposition was most pronounced in R406W MAPT (pre)symptomatic mutation carriers, which is associated with both 3R and 4R tau accumulation. Thus, [18F]flortaucipir may serve as an early biomarker for MAPT mutation carriers in mutations that cause 3R/4R tauopathies.
引用
- Wolters EE, Papma JM, Verfaillie SCJ, et al. [18F]Flortaucipir PET Across Various MAPT Mutations in Presymptomatic and Symptomatic Carriers. Neurology. 2021. PMID: 34210823. doi:10.1212/WNL.0000000000012448
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。